Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization.

ISRN oncology Pub Date : 2013-09-15 eCollection Date: 2013-01-01 DOI:10.1155/2013/538376
Mohamed E Salem, Nitin Jain, Gregory Dyson, Stephanie Taylor, Sherif M El-Refai, Minsig Choi, Anthony F Shields, Jeffery Critchfield, Philip A Philip
{"title":"Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization.","authors":"Mohamed E Salem,&nbsp;Nitin Jain,&nbsp;Gregory Dyson,&nbsp;Stephanie Taylor,&nbsp;Sherif M El-Refai,&nbsp;Minsig Choi,&nbsp;Anthony F Shields,&nbsp;Jeffery Critchfield,&nbsp;Philip A Philip","doi":"10.1155/2013/538376","DOIUrl":null,"url":null,"abstract":"<p><p>Background. In patients with hepatocellular carcinoma, selection criteria for transarterial hepatic selective internal radiotherapy are imprecise. Additionally, radiographic parameters to predict outcome of transarterial hepatic selective internal radiotherapy have not been fully characterized. Patients and methods. Computed tomography (CT) scans of 23 patients with unresectable primary hepatocellular carcinoma before and after transarterial hepatic selective internal radiotherapy with yttrium-90 microspheres were retrospectively reviewed. Selected radiographic parameters were evaluated and correlated with progression-free survival and overall survival. Response to treatment was assessed with Response RECIST 1.1 and Morphology, Attenuation, Size, and Structure (MASS) criteria. Results. On the post-SIRT CT, 68% of tumors demonstrated decreased size (median decrease of 0.8 cm, P = 0.3); 64% had decreased attenuation (median decrease 5.7 HU, P = 0.06), and 48% demonstrated increased tumor necrosis (P < 0.001). RECIST-defined partial response was seen in 10% patients, stable disease in 80%, and 10% had disease progression. Median progression-free survival was 3.9 months (range, 3.3 to 7.3), and median overall survival was 11.2 months (7.1 to 31.1). Pretreatment lower hepatopulmonary shunt fraction, central hypervascularity, and well-defined tumor margins were associated with improved progression-free survival. Conclusion. In patients with unresectable hepatocellular carcinoma, pretreatment CT parameters may predict favorable response to SIRT and improve patient selection. </p>","PeriodicalId":89399,"journal":{"name":"ISRN oncology","volume":" ","pages":"538376"},"PeriodicalIF":0.0000,"publicationDate":"2013-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/538376","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/538376","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

Background. In patients with hepatocellular carcinoma, selection criteria for transarterial hepatic selective internal radiotherapy are imprecise. Additionally, radiographic parameters to predict outcome of transarterial hepatic selective internal radiotherapy have not been fully characterized. Patients and methods. Computed tomography (CT) scans of 23 patients with unresectable primary hepatocellular carcinoma before and after transarterial hepatic selective internal radiotherapy with yttrium-90 microspheres were retrospectively reviewed. Selected radiographic parameters were evaluated and correlated with progression-free survival and overall survival. Response to treatment was assessed with Response RECIST 1.1 and Morphology, Attenuation, Size, and Structure (MASS) criteria. Results. On the post-SIRT CT, 68% of tumors demonstrated decreased size (median decrease of 0.8 cm, P = 0.3); 64% had decreased attenuation (median decrease 5.7 HU, P = 0.06), and 48% demonstrated increased tumor necrosis (P < 0.001). RECIST-defined partial response was seen in 10% patients, stable disease in 80%, and 10% had disease progression. Median progression-free survival was 3.9 months (range, 3.3 to 7.3), and median overall survival was 11.2 months (7.1 to 31.1). Pretreatment lower hepatopulmonary shunt fraction, central hypervascularity, and well-defined tumor margins were associated with improved progression-free survival. Conclusion. In patients with unresectable hepatocellular carcinoma, pretreatment CT parameters may predict favorable response to SIRT and improve patient selection.

Abstract Image

Abstract Image

Abstract Image

放射学参数在预测肝细胞癌患者用钇-90微球放射栓塞治疗预后中的作用。
背景。在肝癌患者中,经动脉肝选择性放射治疗的选择标准是不精确的。此外,预测经动脉肝选择性内放射治疗结果的影像学参数尚未得到充分表征。患者和方法。本文回顾性分析了23例不可切除原发性肝癌经动脉选择性肝内放疗前后的CT扫描结果。评估选定的影像学参数,并将其与无进展生存期和总生存期相关联。采用反应RECIST 1.1和形态、衰减、大小和结构(MASS)标准评估治疗反应。结果。在sirt后的CT上,68%的肿瘤缩小(中位缩小0.8 cm, P = 0.3);64%的肿瘤衰减减少(中位数减少5.7 HU, P = 0.06), 48%的肿瘤坏死增加(P < 0.001)。10%的患者出现部分缓解,80%的患者病情稳定,10%的患者出现疾病进展。中位无进展生存期为3.9个月(范围3.3 - 7.3),中位总生存期为11.2个月(7.1 - 31.1)。预处理降低肝肺分流分数、中枢性血管增生和明确的肿瘤边缘与改善无进展生存相关。结论。对于不能切除的肝细胞癌患者,预处理CT参数可以预测SIRT的良好反应并改善患者选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信